Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Current Opinion in Genetics & Development
|
April 17, 2017
The promise of epigenetic therapy: reprogramming the cancer epigenome
Andrew D Kelly, Jean-Pierre J Issa
JCO Precision Oncology
|
August 23, 2021
<i>STRN-ALK</i> Fusion-Positive Case of Breast Cancer With Response to Alectinib
Andrew D Kelly, Tom Wiklund, Juha Kononen, et al.
Cancer Journal (Sudbury, Mass.)
|
September 20, 2017
Epigenetics and Precision Oncology
Rachael J Werner, Andrew D Kelly, Jean-Pierre J Issa
Plos One
|
October 11, 2011
Metabolomic profiling from formalin-fixed, paraffin-embedded tumor tissue using targeted LC/MS/MS: application in sarcoma
Andrew D Kelly, Susanne B Breitkopf, Min Yuan, et al.
Cancer Research
|
June 13, 2018
TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer
Charly Ryan Good, Shoghag Panjarian, Andrew D Kelly, et al.
Leukemia
|
March 21, 2018
Demethylator phenotypes in acute myeloid leukemia
Andrew D Kelly, Jozef Madzo, Priyanka Madireddi, et al.
Genomics
|
April 9, 2013
Next-generation sequencing and microarray-based interrogation of microRNAs from formalin-fixed, paraffin-embedded tissue: preliminary assessment of cross-platform concordance
Andrew D Kelly, Katherine E Hill, Mick Correll, et al.
Oncotarget
|
April 1, 2015
MicroRNA-155 expression is independently predictive of outcome in chordoma
Eiji Osaka, Andrew D Kelly, Dimitrios Spentzos, et al.
Journal for Immunotherapy of Cancer
|
November 24, 2021
Pan-cancer landscape of <i>CD274</i> (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response
Andrew D Kelly, Karthikeyan Murugesan, Zheng Kuang, et al.
Clinical Epigenetics
|
July 24, 2019
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia
Woonbok Chung, Andrew D Kelly, Patricia Kropf, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Current Opinion in Genetics & Development
|
April 17, 2017
The promise of epigenetic therapy: reprogramming the cancer epigenome
Andrew D Kelly, Jean-Pierre J Issa
JCO Precision Oncology
|
August 23, 2021
<i>STRN-ALK</i> Fusion-Positive Case of Breast Cancer With Response to Alectinib
Andrew D Kelly, Tom Wiklund, Juha Kononen, et al.
Cancer Journal (Sudbury, Mass.)
|
September 20, 2017
Epigenetics and Precision Oncology
Rachael J Werner, Andrew D Kelly, Jean-Pierre J Issa
Plos One
|
October 11, 2011
Metabolomic profiling from formalin-fixed, paraffin-embedded tumor tissue using targeted LC/MS/MS: application in sarcoma
Andrew D Kelly, Susanne B Breitkopf, Min Yuan, et al.
Cancer Research
|
June 13, 2018
TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer
Charly Ryan Good, Shoghag Panjarian, Andrew D Kelly, et al.
Leukemia
|
March 21, 2018
Demethylator phenotypes in acute myeloid leukemia
Andrew D Kelly, Jozef Madzo, Priyanka Madireddi, et al.
Genomics
|
April 9, 2013
Next-generation sequencing and microarray-based interrogation of microRNAs from formalin-fixed, paraffin-embedded tissue: preliminary assessment of cross-platform concordance
Andrew D Kelly, Katherine E Hill, Mick Correll, et al.
Oncotarget
|
April 1, 2015
MicroRNA-155 expression is independently predictive of outcome in chordoma
Eiji Osaka, Andrew D Kelly, Dimitrios Spentzos, et al.
Journal for Immunotherapy of Cancer
|
November 24, 2021
Pan-cancer landscape of <i>CD274</i> (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response
Andrew D Kelly, Karthikeyan Murugesan, Zheng Kuang, et al.
Clinical Epigenetics
|
July 24, 2019
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia
Woonbok Chung, Andrew D Kelly, Patricia Kropf, et al.
Page
of 2